E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Aneurysmal bone cysts, giant cell granuloma, other giant cell rich lesions (primary bone, non-malignant) |
Aneurysmatische botcysten, reuscelgranulomen, andere reuscelrijke lesies (primair uitgaande van bot, niet maligne) |
|
E.1.1.1 | Medical condition in easily understood language |
Aneurysmal bone cysts, giant cell granuloma, other benign giant cell rich lesions of bone |
Aneurysmatische botcysten, reuscelgranulomen, andere goedaardige reuscelrijke lesies van het bot |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Musculoskeletal Diseases [C05] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10018252 |
E.1.2 | Term | Giant cell granuloma peripheral |
E.1.2 | System Organ Class | 100000004856 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10004430 |
E.1.2 | Term | Benign osteoblastoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10008686 |
E.1.2 | Term | Chondroblastoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008733 |
E.1.2 | Term | Chondromyxoid fibroma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10002362 |
E.1.2 | Term | Aneurysmal bone cyst |
E.1.2 | System Organ Class | 10028395 - Musculoskeletal and connective tissue disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Subjects with salvageable giant cell rich tumors: - To evaluate subjects who do not require surgery during the study - To evaluate subjects who are able to undergo a less morbid surgical procedure compared with the planned surgical procedure at baseline during the study
Subjects with unsalvageable giant cell rich tumors (combined objective): - To evaluate disease control: o Radiological response assessed by combined RECIST, PET, inverse Choi when available AND/OR o No progression at 1 year (based on disease assessment) - Stable pain score, defined as ≤ 1 point increase on ‘worst pain’ question in Brief Pain Inventory - short form (BPI-SF) |
Patienten met operabele reuscelrijke tumoren: - Evalueren van patienten bij wie operatie achterwege gelaten kan worden gedurende de studie - Evalueren van patienten welke minder uitgebreide chirurgie kunnen ondergaan dan initieel gepland
Patienten met inoperabele reuscelrijke tumoren - Evalueren van controle van de ziekte o Radiologische respons bepaald middels gecombineerd RECIST, PET, inverse Choi criteria waar beschikbaar EN/OF o Aanwezigheid progressie van 1 jaar (bepaald middels ziekte evaluatie arts) - Stabiele pijnscore, gedefinieerd als ≤ 1 punt toename op de 'ergste pijn' vraag in de Korte Pijn Vragenlijst (BPI-SF) |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate the safety and tolerability of denosumab in subjects with giant cell rich tumors - To evaluate the proportion of recurrences after denosumab followed by surgery - To evaluate symptomatic improvement after denosumab in subjects with giant cell rich tumors - To evaluate time to surgery (for subjects with salvageable disease), time to recurrence after surgery, progression free survival
|
Secundair - Evalueren van veiligheid en tolerabiliteit van denosumab in patiënten met reuscelrijke tumoren - Evalueren van hoeveelheid recidieven na behandeling met denosumab gevolgd door chirurgie - Evalueren van symptomatische verbetering na denosumab in patiënten met reuscelrijke tumoren - Evalueren van 'tijd tot chirurgie'(voor patiënten met operabele ziekte), tijd tot recidief na chirurgie, en progressie vrije overleving |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Translational research - Translational studies. Systematic analysis of pathologic and molecular markers on tumor material, including evaluation of pathological response for subjects undergoing surgery |
Translationeel onderzoek - Systematische analyse van pathologische en moleculaire markers op tumor materiaal, inclusief evaluatie van pathologische respons na tumor resectie voor patiënten met operabele ziekte |
|
E.3 | Principal inclusion criteria |
The population will consist of patients with the following tumor types: - Pathologically proven giant cell rich tumor • ABC • GCG • Other giant cell rich lesions (primary bone, non-malignant, pathology and radiology to be reviewed during multidisciplinary meeting LUMC)
- Patients with surgically unsalvageable disease (e.g., sacral, spinal giant cell rich tumors, or multiple lesions including pulmonary metastases) OR patients whose planned surgery includes joint resection, limb amputation, hemipelvectomy or surgical procedure resulting in severe morbidity - Measurable evidence of active disease within 1 year before study enrollment - Albumin-adjusted serum calcium level ≥ 2.0 mmol/L (8.0 mg/dL) - Aged 18 years and up and skeletally mature - ECOG performance status 0, 1 or 2 - Written signed informed consent |
De volgende tumortypes worden geïncludeerd: - Aneurysmatische botcysten - Reuscelgranulomen - Overige benigne, reuscelrijke lesies van het bot (pathologie en radiologie worden geëvalueerd tijdens multidisciplinair overleg in het LUMC)
- Patiënten met niet operabele ziekte (b.v. sacraal of spinaal gelokaliseerd, of multipele laesies inclusief pulmonale metastasen) OF patiënten voor wie geplande chirurgie gewrichtsresectie, amputatie van ledematen, hemipelvectomie of andere ernstig invaliderende chirurgie omvat - Bewijs van ziekteactiviteit in het jaar voor studiedeelname - Gecorrigeerd serum calcium ≥ 2.0 mmol/L (8.0 mg/dL) - Leeftijd ≥ 18 jaar en een volwassen skeletleeftijd - ECOG performance status 0, 1 of 2 - Schriftelijk toestemming gegeven |
|
E.4 | Principal exclusion criteria |
- Known or suspected current diagnosis of classic GCTB - Known or suspected current diagnosis of underlying malignancy including but not limited to high-grade sarcoma, osteosarcoma, fibrosarcoma, malignant giant cell sarcoma - Known or suspected current diagnosis of brown cell tumor of hyperparathyroidism, Paget’s disease or cherubism - Known or suspected current diagnosis of primary soft tissue tumor with invasion of the bone - Known diagnosis of other malignancy within the past 5 years (patients with definitively treated basal cell carcinoma and cervical carcinoma in situ are permitted) - Previous treatment with denosumab (with the exception of patients eligible for re-treatment with denosumab after completing this study) - Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw - Active dental or jaw condition which requires oral surgery, including tooth extraction - Non-healed dental/oral surgery - Planned invasive dental procedure for the course of the study - Known hypersensitivity to denosumab - Known hypersensitivity to products to be administered during the study (calcium and/or vitamin D) - Currently receiving other specific treatment for giant cell rich tumors of bone (e.g., radiation, chemotherapy or embolization) - Concurrent bisphosphonate treatment - Major surgery less than 4 weeks prior to start of treatment - Treatment with other investigational device or drug 30 days prior to study enrollment - Unstable systemic disease including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months before study enrollment - Patient is pregnant or breast feeding, or planning to become pregnant within 5 months after the EOT visit - Patient, or partner of patient, of child bearing potential is not willing to use a highly effective method of contraception during treatment and for 5 months after the EOT visit - Patient has any kind of disorder that compromises the ability of the patient to give written informed consent and/or to comply with study procedures |
- Bewezen of verdenking op actuele diagnose klassieke reusceltumor van het bot - Bewezen of verdenking op actuele diagnose van onderliggende maligniteit, inclusief maar niet gelimiteerd tot hooggradig sarcoom, osteosarcoom, fibrosarcoom, maligne reuscelsarcoom - Bewezen of verdenking op actuele diagnose van ‘bruine tumor’ met hyperparathyreoïdie, ziekte van Paget of cherubisme - Bewezen of verdenking op actuele diagnose van primaire weke delen tumor met invasie in het bot - Bewezen of verdenking op andere maligniteit in de 5 jaar voor studiedeelname (patiënten met behandeld basaalcelcarcinoom en cervixcarcinoom in situ mogen wel deelnemen) - Eerdere behandeling met denosumab (uitgezonderd patiënten welke in aanmerking komen voor herstart van denosumab na afronden van deze studie) - Voorgeschiedenis of actuele diagnose osteonecrose of osteomyelitis van de kaak - Actieve tandheelkundige of kaakaandoening waarvoor orale chirurgie, inclusief gebitsextractie, noodzakelijk is - Niet volledig geheelde tandheelkundige of orale chirurgie - Geplande invasieve tandheelkundige procedure gedurende het beloop van de studie - Bekende hypersensitiviteit voor denosumab - Bekende hypersensitiviteit voor medicamenten welke tijdens de studie toegediend worden (calcium en/of vitamine D preparaten) - Gelijktijdig ondergaan van andere behandeling gericht op reuscelrijke tumoren van het bot (b.v. radiotherapie, chemotherapie of embolisatie) - Gelijktijdige behandeling met bisfosfonaten - Majeure chirurgie binnen 4 weken voor start van de studiebehandeling - Behandeling met andere geneesmiddelen of devices in het kader van wetenschappelijk onderzoek in de 30 dagen voor enrollment in de studie - Onstabiele systemische aandoening inclusief actieve infectie, ongecontroleerde hypertensie, onstabiele angina pectoris, hartfalen of myocardinfarct binnen 6 maanden voor enrollment in de studie - Patiënt is zwanger of geeft borstvoeding, of voorziet binnen 5 maanden na het einde studie bezoek zwanger te raken - Vrouwelijke vruchtbare patiënt of vruchtbare partner van patient, welke niet bereid is om een zeer effectieve methode van anticonceptie toe te passen gedurende de studiedeelname en tot 5 maanden na het einde studie bezoek - Patiënt heeft een aandoening die het geven van schriftelijke toestemming en/of het opvolgen van de studieprocedures onmogelijk maakt |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Subjects with salvageable giant cell rich tumors: 1. The proportion of subjects who do not require surgery during the study 2. The proportion of subjects undergoing the planned versus performed type of surgery during the study
Subjects with unsalvageable giant cell rich tumors (combined endpoint): 3. Disease control: 3.1 Radiological response assessed by combined RECIST, PET, inverse Choi when available AND/OR 3.2 No progression at 1 year (based on disease assessment) 4. Stable pain score, defined as ≤ 1 point increase on ‘worst pain’ question in BPI-SF |
Patiënten met operabele reuscelrijke tumoren: 1. Proportie van patiënten bij wie operatie achterwege gelaten kan worden tijdens de studie 2. Proportie van patiënten welke minder uitgebreide chirurgie kunnen ondergaan dan initieel gepland
Patiënten met inoperabele reuscelrijke tumoren (gecombineerd eindpunt) 3. Ziekte controle 3.1 Radiologische respons bepaald middels gecombineerde RECIST, PET, inverse Choi criteria waar beschikbaar EN/OF 3.2 Geen progressie na 1 jaar (bepaald middels ziekte evaluatie arts) 4. Stabiele pijnscore, gedefinieerd als ≤ 1 punt toename op de 'ergste pijn' vraag in de Korte Pijn Vragenlijst (BPI-SF) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
1. evaluation during whole length of study 2. evaluation during whole length of study
3.1 imaging every 12 weeks, evaluation at 1 year 3.2 questionnaire every 4 weeks, evaluation at 1 year 4. questionnaire every 4 weeks, evaluation at 1 year |
1. gedurende hele lengte studie 2. gedurende hele lengte studie
3.1 beeldvorming elke 12 weken, evaluatie na 1 jaar 3.2 vragenlijst elke 4 weken, evaluatie na 1 jaar 4. vragenlijst elke 4 weken, evaluatie na 1 jaar |
|
E.5.2 | Secondary end point(s) |
1. Frequency of adverse events (AEs), as determined by Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03 criteria 2. The proportion of subjects with disease recurrence after denosumab followed by surgery during the study 3. Symptomatic improvement in the European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire C30 (EORTC QLC-30) / BPI-SF, including: 3.1) Change from baseline at 1 year, and 3.2) Time to improvement in pain and time to worsening of pain 4. Time to surgery (for subjects with salvageable disease), time to recurrence after surgery, progression free survival |
1. Frequentie van adverse events, volgens CTCAE v. 4.03 criteria 2. Proportie van patiënten bij wie ziekte recidiveert na denosumab behandeling gevolgd door chirurgie 3. Symptomatische verbetering op EORTC Kwaliteit van Leven C30 vragenlijst en Korte Pijn Vragenlijst (BPI-SF), inclusief: 3.1) Verandering t.o.v. baseline na 1 jaar, en 3.2) Tijd tot verbetering, en tijd tot verslechtering van pijnklachten 4. Tijd tot chirurgie (voor patiënten met operabele ziekte), tijd tot recidief na chirurgie en progressie vrije overleving |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1. AE registration every 4 weeks, evaluation after 1 jaar 2. evaluation during whole length of study 3.1 questionnaire every 4 weeks, evaluation at 1 year 3.2 evaluation during whole length of study 4. evaluation during whole length of study |
1. AE registratie elke 4 weken, evaluatie na 1 jaar 2. gedurende hele lengte studie 3.1 vragenlijst elke 4 weken, evaluatie na 1 jaar 3.2 gedurende hele lengte studie 4. gedurende hele lengte studie |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Translational research - Pathologic and molecular markers on tumor material - Evaluation / proportion of subjects with pathological response for subjects undergoing surgery |
Translationeel onderzoek - Pathologische en moleculaire markers op tumor materiaal - Evaluatie / proportie van pathologische respons na tumor resectie voor patiënten met operabele ziekte |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 6 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study is when all subjects enrolled have completed at least 60 months on study (treatment plus follow-up), or until death or loss to follow-up, whichever comes first. |
Einde van de studie is wanneer alle geincludeerde proefpersonen 60 maanden studiedeelname hebben volbracht (behandeling + followup), of tot aan overlijden of verlies in followup (afhankelijk van welke gebeurtenis zich als eerst voordoet). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |